SSSelin Sen

Selin Sen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Selin Sen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • Raphaëlle Klitting

    Unité des Virus Émergents (UVE: Aix-Marseille Univ, Corsica Univ, IRD190, Inserm1207, IRBA) , Marseille

    2 shared publications
  • Albin Fontaine

    Affiliations Unité des Virus Émergents (UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, Inserm 1207, IRBA), France, Institut de Recherche Biomédicale des Armées (IRBA), Unité de virologie, Marseille, France

    1 shared publication
  • Franck Touret

    Unite des Virus Emergents (UVE: Aix-Marseille Univ, Universita di Corsica, IRD 190, Inserm 1207, IRBA), France

    1 shared publication
  • Geraldine Piorkowski

    Unité des Virus Émergents, UVE: Aix-Marseille Univ, Università di Corsica, IRD 190, INSERM 1207, IRBA

    1 shared publication
  • Gilda Grard

    Unité des Virus Émergents (Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France

    1 shared publication
  • Guillaume André Durand

    Unité des Virus Émergents (Aix-Marseille Université, Università di Corsica, IRD 190, Inserm 1207, IRBA), Marseille, France

    1 shared publication

Latest Publications

  • Open Access

    Dengue virus outbreak in Cochabamba, Bolivia

    by Paola Mariela Saba Villarroel, Selin Sen, Raphaëlle Klitting, Laura Pezzi, Geraldine Piorkowski, Norma Villavicencio Siles, Sineewanlaya Wichit

    With Aedes aegypti expanding to higher altitudes, dengue virus (DENV) cases soared to record levels in 2024 in Cochabamba, Bolivia (2,558 meters above sea level). Using genome sequencing, we identified at least two distinct clades of DENV-2 genotype II circulating during the outbreak.

  • Open Access

    Genomic surveillance reveals a dengue 2 virus epidemic lineage with a marked decrease in sensitivity to Mosnodenvir

    by Hawa Sophia Bouzidi, Selin Sen, Géraldine Piorkowski, Laura Pezzi, Nazli Ayhan, Albin Fontaine, Thomas Canivez, Manon Geulen, Rayane Amaral, Gilda Grard, et al.

    Dengue fever is the most important arbovirosis for public health, with more than 5 million cases worldwide in 2023. Mosnodenvir is the first anti-dengue compound with very high preclinical pan-serotype activity, currently undergoing phase 2 clinical evaluation. Here, by analyzing dengue virus (DENV) genomes from the 2023-2024 epidemic in the French Caribbean Islands, we show that they all exhibit mutation NS4B:V91A, previously associated with a marked decrease in sensitivity to mosnodenvir in vitro. Using antiviral activity tests on four clinical and reverse-genetic strains, we confirm a marked decrease in mosnodenvir sensitivity for DENV-2 ( > 1000 fold). Finally, combining phylogenetic analysis and experimental testing for resistance, we find that virus lineages with low sensitivity to mosnodenvir due to the V91A mutation likely emerged multiple times over the last 30 years in DENV-2 and DENV-3. These results call for increased genomic surveillance, in particular to track lineages with resistance mutations. These efforts should allow to better assess the activity profile of DENV treatments in development against circulating strains.